Encompass Health (AMEX:EHC) had its target price reduced by Raymond James from $80.00 to $75.00 in a research note issued to investors on Wednesday morning, BenzingaRatingsTable reports. They currently have an outperform rating on the stock.
Other equities research analysts have also recently issued reports about the company. BMO Capital Markets began coverage on Encompass Health in a report on Thursday, June 27th. They issued an outperform rating and a $72.00 target price on the stock. Barclays raised Encompass Health from an equal weight rating to an overweight rating and lifted their target price for the stock from $68.00 to $70.00 in a report on Thursday, May 30th. Finally, Zacks Investment Research cut Encompass Health from a hold rating to a sell rating in a report on Tuesday, July 30th. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $75.00.
Encompass Health has a twelve month low of $40.86 and a twelve month high of $59.29.
The company also recently announced a quarterly dividend, which was paid on Monday, July 15th. Stockholders of record on Monday, July 1st were issued a $0.27 dividend. The ex-dividend date of this dividend was Friday, June 28th. This represents a $1.08 annualized dividend and a dividend yield of ∞.
Encompass Health Company Profile
Encompass Health Corporation, formerly HealthSouth Corporation, is a provider of post-acute healthcare services, offering both facility-based and home-based post-acute services in 35 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies.
Read More: What is the Current Ratio?
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.